The FDA granted orphan designation to a treatment of systemic sclerosis being developed by Kyverna Therapeutics, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna announces presentation on KYV-101 at ECTRIMS
- Kyverna Therapeutics Announces Executive Leadership Changes
- Kyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
- Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation
- Kyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright